"So I guess nothing in this world is absolute including surveillance testing. But certainly for our own purposes as we look at our overall BSE program and any changes we might need to make to our program, certainly in the context of communicating with our trading partners in terms of the prevalence or lack of prevalence of the disease in this country, this surveillance program is of paramount importance.
And so the bottom line is, the more samples we test, the greater accuracy and the more confidence we can say whether or not we have the disease and at what prevalence.
ROGERS: That concludes today's technical briefing. As always, if you have further questions you can check out our website at www.aphis.usda.gov.
Thank you, and have a nice day."
(end transcript)
(Distributed by the Bureau
And so the bottom line is, the more samples we test, the greater accuracy and the more confidence we can say whether or not we have the disease and at what prevalence.
ROGERS: That concludes today's technical briefing. As always, if you have further questions you can check out our website at www.aphis.usda.gov.
Thank you, and have a nice day."
(end transcript)
(Distributed by the Bureau